Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Opinion
  • Published:

Does cardiovascular protection translate into renal protection?

Nature Reviews Cardiology volume 11, pages 742–746 (2014)Cite this article

Subjects

Abstract

Cardiovascular and renal disease often have similar origins and shared risk factors. With the progression of chronic kidney disease (CKD), additional risk factors develop, contributing to the evolution of both diseases. Progression of CKD has been primarily investigated in patients with established diabetic nephropathy and severely increased albuminuria, in cohorts smaller than those necessary for studies of cardiovascular outcomes. Consequently, simultaneous cardiovascular and renal protection was not demonstrated clearly in these studies. Nevertheless, data from some clinical trials in the field of arterial hypertension have demonstrated that cardiovascular and renal protection can be attained using the same therapy. Further investigation on factors that promote rapid progression of cardiovascular disease and CKD should result in new therapies to improve the outcome of patients presenting with both diseases.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Cross-talk between CVD and CKD.
Figure 2: Risk of developing CKD by categories of GFR and albuminuria.

Similar content being viewed by others

References

  1. Ruilope, L. M. & Bakris, G. L. Renal function and target organ damage in hypertension. Eur. Heart J. 32, 1599–1604 (2011).

    Article  Google Scholar 

  2. Gansevoort, R. T. et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 382, 339–352 (2013).

    Article  Google Scholar 

  3. Samuelsson, O. Hypertension in middle-aged men. Management, morbidity and prognostic factors during long-term hypertensive care. Acta Med. Scand. Suppl. 702, 1–79 (1985).

    CAS  PubMed  Google Scholar 

  4. Shulman, N. B. et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the Hypertension Detection and Follow-Up Program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 13 (5 Suppl.), I80–I93 (1989).

    Article  CAS  Google Scholar 

  5. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. Suppl. [online], (2012).

  6. Tonelli, M. et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 380, 807–814 (2012).

    Article  Google Scholar 

  7. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int. Suppl. [online], (2013).

  8. Nitsch, D. et al. Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis. BMJ 346, f324 (2013).

    Article  Google Scholar 

  9. Research News: Low eGFR and high albuminuria predict end stage kidney disease and death at all ages. BMJ 345, e7478 (2012).

  10. Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861–869 (2001).

    Article  CAS  Google Scholar 

  11. Lewis, E. J. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851–860 (2001).

    Article  CAS  Google Scholar 

  12. Ruilope, L. M. et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J. Am. Soc. Nephrol. 12, 218–225 (2001).

    CAS  PubMed  Google Scholar 

  13. Mann, J. F., Gerstein, H. C., Pogue, J., Bosch, J. & Yusuf, S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann. Intern. Med. 134, 629–636 (2001).

    Article  CAS  Google Scholar 

  14. Rahman, M. et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch. Intern. Med. 165, 936–946 (2005).

    Article  CAS  Google Scholar 

  15. Mann, J. F. et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372, 547–553 (2008).

    Article  CAS  Google Scholar 

  16. Lawes, C. M., Vander Hoorn, S. & Rodgers, A. for the International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 371, 1513–1518 (2008).

    Article  Google Scholar 

  17. Huang, Y. et al. Prehypertension and incidence of ESRD: a systematic review and meta-analysis. Am. J. Kidney Dis. 63, 76–83 (2014).

    Article  Google Scholar 

  18. Banegas, J. R. et al. High prevalence of masked uncontrolled hypertension in people with treated hypertension. Eur. Heart J. http://dx.doi.org/10.1093/eurheartj/ehu016.

  19. Mancia, G. et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 34, 2159–2219 (2013).

    Article  Google Scholar 

  20. Dahlöf, B. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366, 895–906 (2005).

    Article  Google Scholar 

  21. Patel, A. et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370, 829–840 (2007).

    Article  CAS  Google Scholar 

  22. de Galan, B. E. et al. Lowering blood pressure reduces renal events in type 2 diabetes. J. Am. Soc. Nephrol. 20, 883–892 (2009).

    Article  CAS  Google Scholar 

  23. Jamerson, K. et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359, 2417–2428 (2008).

    Article  CAS  Google Scholar 

  24. Bakris, G. L. et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 375, 1173–1181 (2010).

    Article  CAS  Google Scholar 

  25. Zanchetti, A. et al. Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. J. Hypertens. 27, 673–679 (2009).

    Article  CAS  Google Scholar 

  26. Yusuf, S. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547–1559 (2008).

    Article  CAS  Google Scholar 

  27. Ruilope, L. M., Segura, J., Fujita, T. & Ritz, E. Renal and cardiovascular events: do they deserve the same consideration in clinical trials? J. Hypertens. 27, 1743–1745 (2009).

    Article  CAS  Google Scholar 

  28. Parving, H. H. et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. 367, 2204–2213 (2012).

    Article  CAS  Google Scholar 

  29. Fried, L. F. et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N. Engl. J. Med. 369, 1892–1903 (2013).

    Article  CAS  Google Scholar 

  30. James, P. A. et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311, 507–520 (2014).

    Article  CAS  Google Scholar 

  31. Weber, M. A. et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J. Clin. Hypertens. (Greenwich) 16, 14–26 (2014).

    Article  Google Scholar 

  32. de Zeeuw, D. et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110, 921–927 (2004).

    Article  CAS  Google Scholar 

  33. Schmieder, R. E. et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J. Am. Soc. Nephrol. 22, 1353–1364 (2011).

    Article  Google Scholar 

  34. Estruch, R. et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N. Engl. J. Med. 368, 1279–1290 (2013).

    Article  CAS  Google Scholar 

  35. Dunkler, D. et al. Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus. JAMA Intern. Med. 173, 1682–1692 (2013).

    CAS  PubMed  Google Scholar 

  36. Wing, R. R. et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N. Engl. J. Med. 369, 145–154 (2013).

    Article  CAS  Google Scholar 

  37. Sarafidis, P. A. & Ruilope, L. M. Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation? Kidney Int. 85, 536–546 (2014).

    Article  CAS  Google Scholar 

  38. Ruilope, L. M. Chronic kidney disease: Blood pressure control in CKD—still a matter of debate. Nat. Rev. Nephrol. 9, 572–573 (2013).

    Article  Google Scholar 

  39. Van Buren, P. N., Adams-Huet, B., Nguyen, M., Molina, C. & Toto, R. D. Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy. Clin. J. Am. Soc. Nephrol. 9, 295–301 (2014).

    Article  CAS  Google Scholar 

  40. Jardine, M. J. et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J. Am. Coll. Cardiol. 56, 956–965 (2010).

    Article  CAS  Google Scholar 

  41. Ninomiya, T. et al. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ 347, f5680 (2013).

    Article  CAS  Google Scholar 

  42. Gorostidi, M. et al. Differences between office and 24-hour blood pressure control in hypertensive patients with CKD: a 5,693-patient cross-sectional analysis from Spain. Am. J. Kidney Dis. 62, 285–294 (2013).

    Article  Google Scholar 

  43. Formentini, I. et al. Current drug development challenges in chronic kidney disease (CKD)—identification of individualized determinants of renal progression and premature cardiovascular disease (CVD). Nephrol. Dial. Transplant. 27 (Suppl. 3), iii81–iii88 (2012).

    CAS  PubMed  Google Scholar 

  44. National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am. J. Kidney Dis. 39 (2 Suppl. I), S1–S266 (2002).

  45. Kidney Disease: Improving Global Outcomes Work Group. KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. [online], (2013).

Download references

Author information

Authors and Affiliations

  1. Hypertension Unit, Instituto de Investigación imas 12, Hospital Universitario 12 de Octubre, Avenida de Córdoba s/n, Madrid, 28041, Spain

    Gema Ruiz-Hurtado & Luis M. Ruilope

Authors
  1. Gema Ruiz-Hurtado
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luis M. Ruilope
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

L.M.R. researched data for the article. Both authors contributed equally to the discussion of the content, wrote the article, and reviewed/edited the manuscript before submission.

Corresponding author

Correspondence to Luis M. Ruilope.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ruiz-Hurtado, G., Ruilope, L. Does cardiovascular protection translate into renal protection?. Nat Rev Cardiol 11, 742–746 (2014). https://doi.org/10.1038/nrcardio.2014.97

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2014.97

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing